+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Venous Ulceration (CVU) - Epidemiology Forecast to 2030

  • ID: 5238595
  • Report
  • January 2021
  • Region: Global
  • 80 pages
  • DelveInsight
1 of 2
This ‘Chronic Venous Ulceration (CVU) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Venous Ulceration (CVU) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Venous Ulceration (CVU) Understanding

Chronic vein ulceration (CVU) is a defect in the skin below the level of the knee that occurs due to improper functioning of venous valves, persisting for more than six weeks with no tendency to heal after three or more months. Hence, also known as leg ulcers or lower limb ulcers or venous ulcers, or venous insufficiency or stasis ulcer.cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.

The venous abnormality that leads to venous leg ulceration may involve abnormalities at different locations in the venous system, of different extent, and different etiologies. Possible causes of venous ulcers include inflammatory processes resulting in leukocyte activation, endothelial damage, platelet aggregation, and intracellular edema. Venous ulcers are often recurrent, and open ulcers can persist from weeks to many years. Severe complications include cellulitis, osteomyelitis, and malignant change. Although the overall prevalence is relatively low, the refractory nature of these ulcers increase the risk of morbidity and mortality and have a significant impact on patient quality of life
The pathophysiology of venous ulcers is not entirely clear. Venous incompetence and associated venous hypertension are thought to be the primary mechanisms for ulcer formation. Factors that may lead to venous incompetence include immobility; ineffective pumping of the calf muscle; and venous valve dysfunction from trauma, congenital absence, venous thrombosis, or phlebitis.

Risk factors for venous ulcers include varicose veins, history of blood clots in the legs (deep vein thrombosis), blockage of the lymph vessels, which causes fluid to build up in the legs, older age, being female, or being tall, family history of venous insufficiency, obesity, pregnancy, smoking, sitting or standing for long periods (usually for work) and fracture of a long bone in the leg or other serious injuries, such as burns or muscle damage. The symptoms of a venous ulcer include pain, itching, and swelling in the affected area. There may also be discolored, or hardened skin around the ulcer, and the sore may produce a foul-smelling discharge.

Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Venous Ulcers, Diagnosed Prevalent Cases of Venous Ulcers , Diagnosed Prevalent Cases of Venous Leg Ulcers, Type-specific Distribution of Venous Ulcers, Gender-specific Distribution of Venous Ulcers and Age-specific Distribution of Venous Ulcers in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Chronic Venous Ulceration (CVU) Detailed Epidemiology Segmentation
  • The prevalent population of Venous Ulcers in the seven major markets was be 4,231,024 in 2020.
  • The diagnosed prevalent population of Chronic Venous Ulcers in the seven major markets is estimated to be 2,004,905 in 2020.
  • The diagnosed prevalent population of Venous Ulcers in the United States was 2,630,551 in 2020.
  • The diagnosed prevalent population of Venous Leg Ulcers in the United States was estimated to be 2,104,441 in 2020.
  • In the United States, the number of males and females with Venous Ulcers was estimated to 1,052,221 and 1,578,331, respectively, in 2020.
  • Depending on the duration for healing, venous ulcers can be of two types: Acute Venous Ulcers, and Chronic Venous Ulcers. The diagnosed prevalent cases of Acute Venous Ulcers and Chronic Venous Ulcers in the United States were 1,407,345 and 1,223,206 in 2020 .
  • In 2017, the diagnosed prevalence of Venous Ulcers in the United States, was highest in the age group of >70 years, followed by 60-70 years and < 60 years with 2,012,513, 402,503, and 100,626 cases, respectively.
  • In the EU5 countries, the diagnosed prevalence of Venous Ulcers was maximum in Germany with 326,283 cases, followed by the France with 229,729 cases in 2017. While, the least number of cases were in Spain, with 176,037 cases in 2017.
  • In Japan, the diagnosed prevalence of Venous Ulcers is estimated to be 490,734 in 2020.
Scope of the Report
  • The report covers the descriptive overview of Chronic Venous Ulceration (CVU), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Venous Ulceration (CVU).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Prevalent Cases of Venous Ulcers, Diagnosed Prevalent Cases of Venous Ulcers , Diagnosed Prevalent Cases of Venous Leg Ulcers, Type-specific Distribution of Venous Ulcers, Gender-specific Distribution of Venous Ulcers and Age-specific Distribution of Venous Ulcers.
Report Highlights
  • Eleven Year Forecast of Chronic Venous Ulceration (CVU)
  • 7MM Coverage
  • The publisher analysed gender-specific data of Venous Ulcers which suggests that the prevalence of Venous Ulcers is more frequent in females than in males.
  • The publisher has also analysed data on types of CVU, which suggests that Acute Venous Ulcers was more common than Chronic Venous Ulcers.
  • The diagnosed prevalence of venous ulcers and venous leg ulcers was also analysed by the publisher.
  • Age-specific data of Venous Ulcers suggests that prevalence of Venous Ulcers in the US, was highest in the age group of >70 years, followed by 60-70 years and < 60 years.
Key Questions Answered
  • What is the disease risk, burden and unmet needs of Chronic Venous Ulceration (CVU)?
  • What is the historical Chronic Venous Ulceration (CVU) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Chronic Venous Ulceration (CVU) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Venous Ulceration (CVU)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Venous Ulceration (CVU)during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Venous Ulceration (CVU).
  • To understand the future market competition in the Chronic Venous Ulceration (CVU) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Venous Ulceration (CVU) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Venous Ulceration (CVU) market.
  • To understand the future market competition in the Chronic Venous Ulceration (CVU)market.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
Note: Product cover images may vary from those shown
2 of 2
1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Chronic venous ulceration (CVU) Overview at a Glance

5 Disease Background and Overview: Chronic venous ulceration (CVU)
5.1 Symptoms
5.2 Classification
5.3 Pathophysiology
5.4 Pathogenesis
5.5 Prognostic Indicators
5.6 Clinical Characteristics
5.7 Prevention
5.8 Differential diagnosis
5.9. Diagnosis
5.9.1. Trendelenburg test
5.9.2. Perthes test
5.9.3. Doppler auscultation
5.9.4. Leg venography
5.9.5. Contrast‐enhanced computed tomography of the leg
5.9.6. Color Doppler echography of the leg
5.9.7. Magnetic resonance venography of the leg
5.9.8. Venous plethysmography of the lower leg
5.9.9. Ankle-brachial pressure index (ABI or ABPI)

6 Recognized Establishments

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7MM Prevalent Population of Venous Ulcers
7.3 7MM Diagnosed Prevalent Population of Venous Ulcers
7.4 7MM Diagnosed Prevalent Population of Chronic Venous Ulcers (CVU)

8 7MM Epidemiology of Chronic Venous Ulceration (CVU)
8.1.1 Assumptions and Rationale
8.2 United States
8.2.1 Prevalent Cases of Venous Ulcers in the United States
8.2.2 Diagnosed Prevalent Cases of Venous Ulcers in the United States
8.2.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in the United States
8.2.4 Type-specific Distribution of Venous Ulcers in the United States
8.2.5 Gender-specific Distribution of Venous Ulcers in the United States
8.2.6 Age-specific Distribution of Venous Ulcers in the United States
8.3 EU5 Countries
8.4 Germany
8.4.1 Prevalent Cases of Venous Ulcers in Germany
8.4.2 Diagnosed Prevalent Cases of Venous Ulcers in Germany
8.4.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany
8.4.4 Type-specific Distribution of Venous Ulcers in Germany
8.4.5 Gender-specific Distribution of Venous Ulcers in Germany
8.4.6 Age-specific Distribution of Venous Ulcers in Germany
8.5 France
8.5.1 Prevalent Cases of Venous Ulcers in France
8.5.2 Diagnosed Prevalent Cases of Venous Ulcers in France
8.5.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in France
8.5.4 Type-specific Distribution of Venous Ulcers in France
8.5.5 Gender-specific Distribution of Venous Ulcers in France
8.5.6 Age-specific Distribution of Venous Ulcers in France
8.6 Italy
8.6.1 Prevalent Cases of Venous Ulcers in Italy
8.6.2 Diagnosed Prevalent Cases of Venous Ulcers in Italy
8.6.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy
8.6.4 Type-specific Distribution of Venous Ulcers in Italy
8.6.5 Gender-specific Distribution of Venous Ulcers in Italy
8.6.6 Age-specific Distribution of Venous Ulcers in Italy
8.7 Spain
8.7.1 Prevalent Cases of Venous Ulcers in Spain
8.7.2 Diagnosed Prevalent Cases of Venous Ulcers in Spain
8.7.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain
8.7.4 Type-specific Distribution of Venous Ulcers in Spain
8.7.5 Gender-specific Distribution of Venous Ulcers in Spain
8.7.6 Age-specific Distribution of Venous Ulcers in Spain
8.8 United Kingdom
8.8.1 Prevalent Cases of Venous Ulcers in the United Kingdom
8.8.2 Diagnosed Prevalent Cases of Venous Ulcers in the United Kingdom
8.8.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in the United Kingdom
8.8.4 Type-specific Distribution of Venous Ulcers in the United Kingdom
8.8.5 Gender-specific Distribution of Venous Ulcers in the United Kingdom
8.8.6 Age-specific Distribution of Venous Ulcers in the United Kingdom
8.9 Japan
8.9.1 Prevalent Cases of Venous Ulcers in Japan
8.9.2 Diagnosed Prevalent Cases of Venous Ulcers in Japan
8.9.3 Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan
8.9.4 Type-specific Distribution of Venous Ulcers in Japan
8.9.5 Gender-specific Distribution of Venous Ulcers in Japan
8.9.6 Age-specific Distribution of Venous Ulcers in Japan

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1: Summary of CVU, Market, Epidemiology and Key Events (2017-2030)
Table 2: Basic CEAP classification system
Table 3: Antibiotic treatments for chronic venous ulcers
Table 4: Functional categories, classifications, characteristics, and Healthcare Common Procedure Coding System classification of wound dressings with active chemical, enzymatic, biologic, or antimicrobial components
Table 5: Surgical treatments for chronic venous ulcers
Table 6: Total Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Table 7: Diagnosed Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Table 8: Diagnosed Prevalent Population of Chronic Venous Ulcers in the 7MM (2017-2030)
Table 9: Prevalence of Venous Ulcers in the US (2017-2030)
Table 10: Diagnosed Prevalence of Venous Ulcers in the US (2017-2030)
Table 11: Diagnosed Prevalent Cases of Venous Leg Ulcers in the US (2017-2030)
Table 12: Type-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 13: Gender-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 14: Age-specific Distribution of Venous Ulcers in the US (2017-2030)
Table 15: Prevalence of Venous Ulcers in Germany (2017-2030)
Table 16: Diagnosed Prevalence of Venous Ulcers in Germany (2017-2030)
Table 17: Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany (2017-2030)
Table 18: Type-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 19: Gender-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 20: Age-specific Distribution of Venous Ulcers in Germany (2017-2030)
Table 21: Prevalence of Venous Ulcers in France (2017-2030)
Table 22: Diagnosed Prevalence of Venous Ulcers in France (2017-2030)
Table 23: Diagnosed Prevalent Cases of Venous Leg Ulcers in France (2017-2030)
Table 24: Type-specific Distribution of Venous Ulcers in France (2017-2030)
Table 25: Gender-specific Distribution of Venous Ulcers in France (2017-2030)
Table 26: Age-specific Distribution of Venous Ulcers in France (2017-2030)
Table 27: Prevalence of Venous Ulcers in Italy (2017-2030)
Table 28: Diagnosed Prevalence of Venous Ulcers in Italy (2017-2030)
Table 29: Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy (2017-2030)
Table 30: Type-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 31: Gender-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 32: Age-specific Distribution of Venous Ulcers in Italy (2017-2030)
Table 33: Prevalence of Venous Ulcers in Spain (2017-2030)
Table 34: Diagnosed Prevalence of Venous Ulcers in Spain (2017-2030)
Table 35: Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain (2017-2030)
Table 36: Type-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 37: Gender-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 38: Age-specific Distribution of Venous Ulcers in Spain (2017-2030)
Table 39: Prevalence of Venous Ulcers in the UK (2017-2030)
Table 40: Diagnosed Prevalence of Venous Ulcers in the UK (2017-2030)
Table 41: Diagnosed Prevalent Cases of Venous Leg Ulcers in the UK (2017-2030)
Table 42: Type-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 43: Gender-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 44: Age-specific Distribution of Venous Ulcers in the UK (2017-2030)
Table 45: Prevalence of Venous Ulcers in Japan (2017-2030)
Table 46: Diagnosed Prevalence of Venous Ulcers in Japan (2017-2030)
Table 47: Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan (2017-2030)
Table 48: Type-specific Distribution of Venous Ulcers in Japan (2017-2030)
Table 49: Gender-specific Distribution of Venous Ulcers in Japan (2017-2030)
Table 50: Age-specific Distribution of Venous Ulcers in Japan (2017-2030)

List of Figures
Figure 1: Chronic venous ulceration (CVU) SWOT Analysis
Figure 2: Pathways from vein to ulcer
Figure 3: Total Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Figure 4: Diagnosed Prevalent Population of Venous Ulcers in the 7MM (2017-2030)
Figure 5: Diagnosed Prevalent Population of Chronic Venous Ulcers in the 7MM (2017-2030)
Figure 6: Prevalent Cases of Venous Ulcers in the US (2017-2030)
Figure 7: Diagnosed Prevalent Cases of Venous Ulcers in the US (2017-2030)
Figure 8: Diagnosed Prevalent Cases of Venous Leg Ulcers in the US (2017-2030)
Figure 9: Type-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 10: Gender-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 11: Age-specific Distribution of Venous Ulcers in the US (2017-2030)
Figure 12: Prevalent Cases of Venous Ulcers in Germany (2017-2030)
Figure 13: Diagnosed Prevalent Cases of Venous Ulcers in Germany (2017-2030)
Figure 14: Diagnosed Prevalent Cases of Venous Leg Ulcers in Germany (2017-2030)
Figure 15: Type-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 16: Gender-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 17: Age-specific Distribution of Venous Ulcers in Germany (2017-2030)
Figure 18: Prevalent Cases of Venous Ulcers in France (2017-2030)
Figure 19: Diagnosed Prevalent Cases of Venous Ulcers in France (2017-2030)
Figure 20: Diagnosed Prevalent Cases of Venous Leg Ulcers in France (2017-2030)
Figure 21: Type-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 22: Gender-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 23: Age-specific Distribution of Venous Ulcers in France (2017-2030)
Figure 24: Prevalent Cases of Venous Ulcers in Italy (2017-2030)
Figure 25: Diagnosed Prevalent Cases of Venous Ulcers in Italy (2017-2030)
Figure 26: Diagnosed Prevalent Cases of Venous Leg Ulcers in Italy (2017-2030)
Figure 27: Type-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 28: Gender-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 29: Age-specific Distribution of Venous Ulcers in Italy (2017-2030)
Figure 30: Prevalent Cases of Venous Ulcers in Spain (2017-2030)
Figure 31: Diagnosed Prevalent Cases of Venous Ulcers in Spain (2017-2030)
Figure 32: Diagnosed Prevalent Cases of Venous Leg Ulcers in Spain (2017-2030)
Figure 33: Type-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 34: Gender-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 35: Age-specific Distribution of Venous Ulcers in Spain (2017-2030)
Figure 36: Prevalent Cases of Venous Ulcers in the UK (2017-2030)
Figure 37: Diagnosed Prevalent Cases of Venous Ulcers in the UK (2017-2030)
Figure 38: Diagnosed Prevalent Cases of Venous Leg Ulcers in the UK (2017-2030)
Figure 39: Type-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 40: Gender-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 41: Age-specific Distribution of Venous Ulcers in the UK (2017-2030)
Figure 42: Prevalent Cases of Venous Ulcers in Japan (2017-2030)
Figure 43: Diagnosed Prevalent Cases of Venous Ulcers in Japan (2017-2030)
Figure 44: Diagnosed Prevalent Cases of Venous Leg Ulcers in Japan (2017-2030)
Figure 45: Type-specific Distribution of Venous Ulcers in Japan (2017-2030)
Figure 46: Gender-specific Distribution of Venous Ulcers in Japan (2017-2030)
Figure 47: Age-specific Distribution of Venous Ulcers in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll